Get started
Aura Biosciences, Inc.Aura Biosciences, Inc.Aura Biosciences, Inc.

Aura Biosciences, Inc.

No trades
Buy AURA
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AURA chart


Full chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪513.92 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.79USD
Net income (FY)
‪−76.41 M‬USD
Revenue (FY)
0.00USD
Shares float
‪42.59 M‬
Beta (1Y)
3.23

Employees


Employees (FY)
89
Change (1Y)
+19 +27.14%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−858.52 K‬USD

About Aura Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Elisabet de los Pinos
Website
aurabiosciences.com
Headquarters
Boston
Founded
2007
FIGI
BBG00226DGM5
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AURA is 10.44 USD — it has decreased by −1.54% in the past 24 hours. Watch Aura Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aura Biosciences, Inc. stocks are traded under the ticker AURA.
AURA stock has fallen by −11.15% compared to the previous week, the month change is a 14.74% rise, over the last year Aura Biosciences, Inc. has showed a 30.34% increase.
We've gathered analysts' opinions on Aura Biosciences, Inc. future price: according to them, AURA price has a max estimate of 24.00 USD and a min estimate of 20.00 USD. Watch AURA chart and read a more detailed Aura Biosciences, Inc. stock forecast: see what analysts think of Aura Biosciences, Inc. and suggest that you do with its stocks.
AURA reached its all-time high on Nov 16, 2021 with the price of 26.16 USD, and its all-time low was 5.99 USD and was reached on Nov 7, 2023. View more price dynamics on AURA chart.
See other stocks reaching their highest and lowest prices.
AURA stock is 6.77% volatile and has beta coefficient of 3.23. Track Aura Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aura Biosciences, Inc. there?
Today Aura Biosciences, Inc. has the market capitalization of ‪513.92 M‬, it has decreased by −7.83% over the last week.
Yes, you can track Aura Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Aura Biosciences, Inc. is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
AURA earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.45 USD resulting in a 8.92% surprise. The estimated earnings for the next quarter are −0.44 USD per share. See more details about Aura Biosciences, Inc. earnings.
Aura Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
AURA net income for the last quarter is ‪−20.34 M‬ USD, while the quarter before that showed ‪−19.71 M‬ USD of net income which accounts for −3.20% change. Track more Aura Biosciences, Inc. financial stats to get the full picture.
No, AURA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 1, 2024, the company has 89.00 employees. See our rating of the largest employees — is Aura Biosciences, Inc. on this list?
Like other stocks, AURA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aura Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aura Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aura Biosciences, Inc. stock shows the buy signal. See more of Aura Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.